Videos

Andrew X. Zhu, MD, PhD, discusses the final results from the phase 3 ClarIDHy study of ivosidenib versus placebo as treatment of patients with previously treated cholangiocarcinoma and an IDH1 mutation.

Ghasson K. Abou-Alfa, MD, discusses the rapid evolution observed in the treatment landscape of hepatocellular carcinoma over the last few years.

Nina Shah, MD, discusses the potential role of idecabtagene vicleucel as treatment of patients with multiple myeloma.

Andrew X. Zhu, MD, PhD, discusses the evolving treatment landscape for patients with hepatocellular carcinoma.

Naomi Haas, MD, discusses the current areas of ongoing research in the treatment landscape for patients with prostate cancer.

Daniel Catenacci, MD, reviews the case of a 71-year-old man with gastric cancer.

Dr Catenacci discusses the DESTINY-Gastric01 study, including personal experience using trastuzumab deruxtecan.

Dr Catenacci highlights clinical trials in HER2-positive gastric cancer that may provide insight on differences in mechanism of resistance from one tumor type to another.

Daniel Catenacci, MD, discusses treatment options after second-line therapy, highlighting options for patients who are PD-L1 positive.

Daniel Catenacci, MD, examines factors that help decide when to switch treatment from first to second line, and when to change mechanism of action in treating gastric carcinoma.

Daniel Catenacci, MD, discusses initial considerations for treatment in patients with microsatellite instability-high/stable, HER2-positive/negative gastric cancer and touches on second-line treatment options.

Dr Catenacci evaluates the case of a 71-year-old man with gastric cancer, and provides insight on molecular testing in gastric cancer and initial treatment options.

Tony S. K. Mok, BMSc, MD, FRCPC, discusses the ADAURA trial of osimertinib in patients with non–small cell lung cancer.

Deepu Madduri, MD, discusses the safety findings from a first-in-human phase 1 study of REGN5458, a BCMA x CD3 bispecific monoclonal antibody, as treatment of patients with relapsed/refractory multiple myeloma.

David M. Waterhouse, MD, MPH, shares advice with community oncologists treating patients with lung cancer.

Christine Dierks, MD, discusses how PD-L1 expression is used to determine treatment for patients with thyroid cancer.

Tapan M. Kadia, MD, discusses the treatment options for patients with newly diagnosed acute myeloid leukemia.

John O. Mascarenhas, MD, discusses the current treatment options for patients with myelofibrosis.

Richard S. Finn, MD, discusses the real-world findings from the REFINE study of patients with unresectable hepatocellular carcinoma who received treatment with regorafenib.

Elizabeth Wulff-Burchfield, MD, discusses the role of immune checkpoint inhibitor combination therapy in metastatic renal cell carcinoma.

William J. Gradishar, MD, discusses the current standard of care for patients with HER2-positive breast cancer, as well as some other promising therapies in this space.

Masahiro Tsuboi, MD, discusses the findings from the phase 3 ADAURA clinical trial of osimertinib as treatment of patients with EGFR-mutated non–small cell lung cancer.

David J. Andorsky, MD, discusses the findings from a subgroup analysis of patients with relapsed/refractory indolent non-Hodgkin lymphoma over the age of 70 in the phase 3b MAGNIFY clinical trial.

Maha Hussain, MD, discusses the current role of PARP inhibitors in the treatment landscape of prostate cancers and where she sees this therapeutic approach evolving in the coming years.

Anne Chiang, MD, associate professor, Medical Oncology, Yale School of Medicine, discusses key takeaways on a presentation around managing non–small cell lung cancer cases in patients with contralateral lung nodules and dominant tumors.

Mehmet K. Samur, PhD, discusses findings from an analysis evaluating high-dose melphalan followed by autologous stem cell transplant as treatment of patients with multiple myeloma compared with the standard of care treatment regimen lenalidomide, bortezomib, and dexamethasone alone.

Neal D. Shore, MD, FACS, discusses the current treatment landscape and upcoming drugs being reviewed by the FDA for the treatment of patients with bladder cancer.

Andrew M. Brunner, MD, shares his key take home message from a phase 1b clinical trial investigating sabatolimab as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.

Justin M. Watts, MD, discusses the key takeaway from the phase 2 Study P-2001 clinical trial, a randomized study comparing the safety and efficacy of pevonedistat in combination with azacitidine in patients with high-risk myelodysplastic syndromes.

Key opinion leaders close the discussion by providing insight into their respective protocols for acute graft-vs-host (GVHD) disease prophylaxis.